Combining CXCR4 antagonists with immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1), cancer vaccines, or adoptive cell therapy holds the potential to convert immunologically “cold” TNBC tumours into “hot” responsive ones. Here, CXCR4 is linked to neoplasm.